AU2002246053B2 - Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors - Google Patents

Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors Download PDF

Info

Publication number
AU2002246053B2
AU2002246053B2 AU2002246053A AU2002246053A AU2002246053B2 AU 2002246053 B2 AU2002246053 B2 AU 2002246053B2 AU 2002246053 A AU2002246053 A AU 2002246053A AU 2002246053 A AU2002246053 A AU 2002246053A AU 2002246053 B2 AU2002246053 B2 AU 2002246053B2
Authority
AU
Australia
Prior art keywords
naphtho
dioxo
isothiazol
group
acid hydroxyamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002246053A
Other languages
English (en)
Other versions
AU2002246053A1 (en
Inventor
Guy Georges
Adelbert Grossmann
Olaf Mundigl
Tim Sattelkau
Wolfgang Von Der Saal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002246053A1 publication Critical patent/AU2002246053A1/en
Application granted granted Critical
Publication of AU2002246053B2 publication Critical patent/AU2002246053B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C07D209/92—Naphthostyrils

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
AU2002246053A 2001-01-27 2002-01-24 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors Ceased AU2002246053B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01101873 2001-01-27
EP01101873.6 2001-01-27
PCT/EP2002/000705 WO2002062773A1 (en) 2001-01-27 2002-01-24 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
AU2002246053A1 AU2002246053A1 (en) 2003-02-13
AU2002246053B2 true AU2002246053B2 (en) 2005-02-17

Family

ID=8176314

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002246053A Ceased AU2002246053B2 (en) 2001-01-27 2002-01-24 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors

Country Status (15)

Country Link
US (1) US7091229B2 (zh)
EP (1) EP1358168B1 (zh)
JP (1) JP3961955B2 (zh)
KR (1) KR100628013B1 (zh)
CN (1) CN1216047C (zh)
AR (1) AR035417A1 (zh)
AT (1) ATE301644T1 (zh)
AU (1) AU2002246053B2 (zh)
BR (1) BR0206738A (zh)
CA (1) CA2432196C (zh)
DE (1) DE60205454T2 (zh)
ES (1) ES2248531T3 (zh)
MX (1) MXPA03006422A (zh)
WO (1) WO2002062773A1 (zh)
ZA (1) ZA200305382B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226855D0 (en) 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
EP1713460A2 (en) * 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
MX2007001550A (es) * 2004-08-09 2007-04-10 Astellas Pharma Inc Compuestos de hidroxiamida que tienen actividad como inhibidores de histona desacetilasa (hdac).
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
ES2288803B1 (es) * 2006-07-07 2008-12-16 Universidad De Granada Derivados de benzo(d)isotiazoles como inhibidores de las histonas desacetilasas.
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
GB0620823D0 (en) 2006-10-19 2006-11-29 Univ London Histone deacetylase inhibitors
TW201716375A (zh) * 2007-06-12 2017-05-16 Achaogen Inc 抗菌劑
WO2009002941A1 (en) * 2007-06-22 2008-12-31 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
JP2010536876A (ja) * 2007-08-21 2010-12-02 アークル インコーポレイテッド Ｈｄａｃインヒビター
US20110044952A1 (en) * 2007-11-27 2011-02-24 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
AU2008338631A1 (en) * 2007-12-14 2009-06-25 Georgetown University Histone deacetylase inhibitors
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010114905A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Peri-fused pyrazolo-pyrimidine compounds
EP3769757A3 (en) * 2013-10-18 2021-10-06 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
EP1057814B1 (en) * 1997-12-25 2005-03-09 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole derivatives
US6271222B1 (en) * 1998-05-28 2001-08-07 Merck & Co., Inc. Penem antibacterial compounds, compositions and methods of treatment
US6221859B1 (en) * 1999-08-27 2001-04-24 Merck & Co., Inc. Carbapenem antibacterial compositions and methods of the treatment

Also Published As

Publication number Publication date
CA2432196A1 (en) 2002-08-15
JP2004517956A (ja) 2004-06-17
EP1358168A1 (en) 2003-11-05
ATE301644T1 (de) 2005-08-15
CN1487925A (zh) 2004-04-07
DE60205454T2 (de) 2006-03-30
ES2248531T3 (es) 2006-03-16
AR035417A1 (es) 2004-05-26
KR20030072607A (ko) 2003-09-15
CN1216047C (zh) 2005-08-24
US7091229B2 (en) 2006-08-15
WO2002062773A1 (en) 2002-08-15
EP1358168B1 (en) 2005-08-10
CA2432196C (en) 2007-11-27
JP3961955B2 (ja) 2007-08-22
BR0206738A (pt) 2004-02-03
US20040077698A1 (en) 2004-04-22
ZA200305382B (en) 2004-10-11
DE60205454D1 (de) 2005-09-15
MXPA03006422A (es) 2003-10-15
KR100628013B1 (ko) 2006-09-26

Similar Documents

Publication Publication Date Title
AU2002246053B2 (en) Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
US6800638B2 (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
AU2002246053A1 (en) Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors
AU2002254991B2 (en) Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
AU2002226397A1 (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
AU2002254991A1 (en) Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
RU2288220C2 (ru) Производные тетралона в качестве противоопухолевых агентов и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired